Status:
RECRUITING
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Lead Sponsor:
Pfizer
Conditions:
Vitiligo
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chro...
Eligibility Criteria
Inclusion
- Participants ≥18 years of age at Screening in Study B7981040. Adolescents (12 to \<18 years of age at Screening in the parent study) are also eligible for this study if approved by the local IRB/EC and regulatory health authority.
- Participants who met the eligibility criteria and completed 52 weeks of study intervention for stable or active nonsegmental vitiligo in Study B7981040
- The BL visit/first dose in Study B7981041 must be within 30 days after the week 52 visit in Study B7981040
Exclusion
- Participant met the parent study (Study 7981040) discontinuation criteria or discontinued the parent study for any safety-related event
- Any active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation
Key Trial Info
Start Date :
January 19 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 23 2027
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06163326
Start Date
January 19 2024
End Date
April 23 2027
Last Update
August 19 2025
Active Locations (74)
Enter a location and click search to find clinical trials sorted by distance.
1
California Dermatology & Clinical Research Institute
Encinitas, California, United States, 92024
2
Marvel Clinical Research
Huntington Beach, California, United States, 92647
3
Wallace Medical Group, Inc
Los Angeles, California, United States, 90056
4
Encore Medical Research of Boynton Beach
Boynton Beach, Florida, United States, 33436